Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805 is registered in ClinicalTrials.gov with Mediar Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Mediar Therapeutics
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 5, 2025
- Completion date
- August 31, 2027
- Enrollment
- 164 (estimated)
- Sites
- 71
Conditions
As the registry lists them; a condition with its own page is linked.